Other languages Revelation Biosciences, Inc.

Equities

REVB

US76135L5075

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-07 EDT			5-day change	1st Jan Change
2.38 ^USD	+1.28%		+12.94%	-84.16%

03-22	Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
03-22	Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-22
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini	03-04
Top Midday Decliners	02-01
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday on Unchanged Fed Rate, Upcoming Earnings	02-01
Top Premarket Decliners	02-01
Top Premarket Gainers	01-31
Top Premarket Gainers	01-29
Revelation Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Revelation Biosciences Inc. Announces Data from Recent Preclinical Studies of the Gemini Formulation Demonstrates Its Therapeutic Potential as A Preventative Therapy Across Multiple Indications Including Infection and Acute Kidney Injury	23-10-12
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla to Board of Directors	23-10-02
Revelation Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Revelation Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board	23-03-13
Revelation Biosciences Prices $15.6 Million Securities Offering; Shares Drop Fourth Consecutive Day	23-02-09
Top Midday Decliners	23-02-09
Revelation Biosciences Prices $15.6 Million Securities Offering; Shares Plunge	23-02-09
Top Premarket Decliners	23-02-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Revelation Biosciences, Inc.

Equities

REVB

US76135L5075

Other languages

Filters